npj Vaccines
(Aug 2023)
An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis
Shivankari Krishnananthasivam,
Hao Li,
Rania Bouzeyen,
Bhuvaneshwari Shunmuganathan,
Kiren Purushotorman,
Xinlei Liao,
Fengjiao Du,
Claudia Guldager Kring Friis,
Felicity Crawshay-Williams,
Low Heng Boon,
Qian Xinlei,
Conrad En Zuo Chan,
Radoslaw Sobota,
Mary Kozma,
Valeria Barcelli,
Guirong Wang,
Hairong Huang,
Andreas Floto,
Pablo Bifani,
Babak Javid,
Paul A. MacAry
Affiliations
Shivankari Krishnananthasivam
Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore
Hao Li
College of Veterinary Medicine, China Agricultural University
Rania Bouzeyen
Division of Experimental Medicine, University of California
Bhuvaneshwari Shunmuganathan
Life Sciences Institute, National University of Singapore
Kiren Purushotorman
Life Sciences Institute, National University of Singapore
Xinlei Liao
National Clinical Laboratory on Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University
Fengjiao Du
National Clinical Laboratory on Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University
Claudia Guldager Kring Friis
Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore
Felicity Crawshay-Williams
Molecular Immunity Unit, University of Cambridge, Department of Medicine, MRC Laboratory of Molecular Biology
Low Heng Boon
Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore
Qian Xinlei
Life Sciences Institute, National University of Singapore
Conrad En Zuo Chan
National Centre for Infectious Diseases, Tan Tock Seng Hospital
Radoslaw Sobota
Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR)
Mary Kozma
Life Sciences Institute, National University of Singapore
Valeria Barcelli
Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore
Guirong Wang
National Clinical Laboratory on Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University
Hairong Huang
National Clinical Laboratory on Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University
Andreas Floto
Molecular Immunity Unit, University of Cambridge, Department of Medicine, MRC Laboratory of Molecular Biology
Pablo Bifani
Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore
Babak Javid
Center for Infectious Disease Research, School of Medicine, Tsinghua University
Paul A. MacAry
Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore
DOI
https://doi.org/10.1038/s41541-023-00710-1
Journal volume & issue
Vol. 8,
no. 1
pp.
1
– 12
Abstract
Read online
Abstract Tuberculosis (TB) is an airborne disease caused by Mycobacterium tuberculosis (Mtb). Whilst a functional role for humoral immunity in Mtb protection remains poorly defined, previous studies have suggested that antibodies can contribute towards host defense. Thus, identifying the critical components in the antibody repertoires from immune, chronically exposed, healthy individuals represents an approach for identifying new determinants for natural protection. In this study, we performed a thorough analysis of the IgG/IgA memory B cell repertoire from occupationally exposed, immune volunteers. We detail the identification and selection of a human monoclonal antibody that exhibits protective activity in vivo and show that it targets a virulence factor LpqH. Intriguingly, protection in both human ex vivo and murine challenge experiments was isotype dependent, with most robust protection being mediated via IgG2 and IgA. These data have important implications for our understanding of natural mucosal immunity for Mtb and highlight a new target for future vaccine development.
Published in npj Vaccines
ISSN
2059-0105 (Online)
Publisher
Nature Portfolio
Country of publisher
United Kingdom
LCC subjects
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website
https://www.nature.com/npjvaccines/
About the journal
WeChat QR code
Close